Vol. 2 No. 9 (2022): September
Reimbursement Reviews

Cenegermin (Oxervate)

Published September 13, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cenegermin ophthalmic solution (Oxervate), 0.002% (20 mcg/mL), topical eye drops.
  • Indication: For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.